|
Gene: BIRC6 |
Gene summary for BIRC6 |
Gene summary. |
Gene information | Species | Human | Gene symbol | BIRC6 | Gene ID | 57448 |
Gene name | baculoviral IAP repeat containing 6 | |
Gene Alias | APOLLON | |
Cytomap | 2p22.3 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q9NR09 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
57448 | BIRC6 | CA_HPV_1 | Human | Cervix | CC | 1.15e-02 | 1.86e-02 | 0.0264 |
57448 | BIRC6 | CCI_1 | Human | Cervix | CC | 3.57e-05 | 1.44e+00 | 0.528 |
57448 | BIRC6 | CCI_2 | Human | Cervix | CC | 1.43e-15 | 1.78e+00 | 0.5249 |
57448 | BIRC6 | CCI_3 | Human | Cervix | CC | 9.75e-19 | 1.19e+00 | 0.516 |
57448 | BIRC6 | HTA11_3410_2000001011 | Human | Colorectum | AD | 5.00e-30 | -6.20e-01 | 0.0155 |
57448 | BIRC6 | HTA11_2951_2000001011 | Human | Colorectum | AD | 1.28e-03 | -7.65e-01 | 0.0216 |
57448 | BIRC6 | HTA11_347_2000001011 | Human | Colorectum | AD | 2.15e-16 | 6.69e-01 | -0.1954 |
57448 | BIRC6 | HTA11_411_2000001011 | Human | Colorectum | SER | 7.50e-09 | 7.07e-01 | -0.2602 |
57448 | BIRC6 | HTA11_3361_2000001011 | Human | Colorectum | AD | 1.77e-06 | -4.63e-01 | -0.1207 |
57448 | BIRC6 | HTA11_866_3004761011 | Human | Colorectum | AD | 1.96e-12 | -5.71e-01 | 0.096 |
57448 | BIRC6 | HTA11_9408_2000001011 | Human | Colorectum | AD | 6.26e-07 | -8.83e-01 | 0.0451 |
57448 | BIRC6 | HTA11_10711_2000001011 | Human | Colorectum | AD | 1.43e-02 | -4.46e-01 | 0.0338 |
57448 | BIRC6 | HTA11_7696_3000711011 | Human | Colorectum | AD | 9.72e-05 | -3.57e-01 | 0.0674 |
57448 | BIRC6 | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 2.56e-04 | 7.71e-01 | 0.3487 |
57448 | BIRC6 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 3.18e-11 | 6.90e-01 | 0.281 |
57448 | BIRC6 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 1.48e-07 | -3.69e-01 | 0.3005 |
57448 | BIRC6 | F007 | Human | Colorectum | FAP | 3.69e-03 | -2.15e-01 | 0.1176 |
57448 | BIRC6 | A001-C-207 | Human | Colorectum | FAP | 5.36e-03 | -1.19e-01 | 0.1278 |
57448 | BIRC6 | A015-C-203 | Human | Colorectum | FAP | 1.70e-36 | -4.81e-01 | -0.1294 |
57448 | BIRC6 | A015-C-204 | Human | Colorectum | FAP | 3.20e-07 | -3.37e-01 | -0.0228 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:200123310 | Cervix | CC | regulation of apoptotic signaling pathway | 96/2311 | 356/18723 | 4.08e-14 | 3.05e-11 | 96 |
GO:005254710 | Cervix | CC | regulation of peptidase activity | 112/2311 | 461/18723 | 6.70e-13 | 3.08e-10 | 112 |
GO:005254810 | Cervix | CC | regulation of endopeptidase activity | 103/2311 | 432/18723 | 1.89e-11 | 5.14e-09 | 103 |
GO:004586110 | Cervix | CC | negative regulation of proteolysis | 80/2311 | 351/18723 | 2.88e-08 | 1.98e-06 | 80 |
GO:200123410 | Cervix | CC | negative regulation of apoptotic signaling pathway | 56/2311 | 224/18723 | 1.39e-07 | 6.70e-06 | 56 |
GO:00513469 | Cervix | CC | negative regulation of hydrolase activity | 81/2311 | 379/18723 | 4.27e-07 | 1.67e-05 | 81 |
GO:00018908 | Cervix | CC | placenta development | 40/2311 | 144/18723 | 4.59e-07 | 1.77e-05 | 40 |
GO:00104669 | Cervix | CC | negative regulation of peptidase activity | 60/2311 | 262/18723 | 1.27e-06 | 4.34e-05 | 60 |
GO:00614588 | Cervix | CC | reproductive system development | 87/2311 | 427/18723 | 1.37e-06 | 4.55e-05 | 87 |
GO:00486088 | Cervix | CC | reproductive structure development | 86/2311 | 424/18723 | 1.90e-06 | 5.97e-05 | 86 |
GO:009719110 | Cervix | CC | extrinsic apoptotic signaling pathway | 52/2311 | 219/18723 | 2.06e-06 | 6.34e-05 | 52 |
GO:001095110 | Cervix | CC | negative regulation of endopeptidase activity | 56/2311 | 252/18723 | 7.43e-06 | 1.74e-04 | 56 |
GO:200123610 | Cervix | CC | regulation of extrinsic apoptotic signaling pathway | 37/2311 | 151/18723 | 2.80e-05 | 4.65e-04 | 37 |
GO:00017018 | Cervix | CC | in utero embryonic development | 71/2311 | 367/18723 | 7.21e-05 | 1.00e-03 | 71 |
GO:00513021 | Cervix | CC | regulation of cell division | 39/2311 | 177/18723 | 2.05e-04 | 2.33e-03 | 39 |
GO:00018928 | Cervix | CC | embryonic placenta development | 22/2311 | 82/18723 | 2.89e-04 | 3.12e-03 | 22 |
GO:00009107 | Cervix | CC | cytokinesis | 37/2311 | 173/18723 | 5.40e-04 | 5.23e-03 | 37 |
GO:200123710 | Cervix | CC | negative regulation of extrinsic apoptotic signaling pathway | 23/2311 | 97/18723 | 1.39e-03 | 1.10e-02 | 23 |
GO:0032465 | Cervix | CC | regulation of cytokinesis | 22/2311 | 92/18723 | 1.55e-03 | 1.20e-02 | 22 |
GO:00607115 | Cervix | CC | labyrinthine layer development | 12/2311 | 44/18723 | 5.76e-03 | 3.30e-02 | 12 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0412014 | Cervix | CC | Ubiquitin mediated proteolysis | 49/1267 | 142/8465 | 4.26e-09 | 7.68e-08 | 4.54e-08 | 49 |
hsa0412015 | Cervix | CC | Ubiquitin mediated proteolysis | 49/1267 | 142/8465 | 4.26e-09 | 7.68e-08 | 4.54e-08 | 49 |
hsa04120 | Colorectum | AD | Ubiquitin mediated proteolysis | 58/2092 | 142/8465 | 1.46e-05 | 1.53e-04 | 9.76e-05 | 58 |
hsa041201 | Colorectum | AD | Ubiquitin mediated proteolysis | 58/2092 | 142/8465 | 1.46e-05 | 1.53e-04 | 9.76e-05 | 58 |
hsa041202 | Colorectum | SER | Ubiquitin mediated proteolysis | 39/1580 | 142/8465 | 6.18e-03 | 3.66e-02 | 2.66e-02 | 39 |
hsa041203 | Colorectum | SER | Ubiquitin mediated proteolysis | 39/1580 | 142/8465 | 6.18e-03 | 3.66e-02 | 2.66e-02 | 39 |
hsa041204 | Colorectum | MSS | Ubiquitin mediated proteolysis | 55/1875 | 142/8465 | 5.02e-06 | 6.00e-05 | 3.68e-05 | 55 |
hsa041205 | Colorectum | MSS | Ubiquitin mediated proteolysis | 55/1875 | 142/8465 | 5.02e-06 | 6.00e-05 | 3.68e-05 | 55 |
hsa0412016 | Endometrium | AEH | Ubiquitin mediated proteolysis | 41/1197 | 142/8465 | 3.42e-06 | 4.27e-05 | 3.13e-05 | 41 |
hsa0412017 | Endometrium | AEH | Ubiquitin mediated proteolysis | 41/1197 | 142/8465 | 3.42e-06 | 4.27e-05 | 3.13e-05 | 41 |
hsa0412023 | Endometrium | EEC | Ubiquitin mediated proteolysis | 41/1237 | 142/8465 | 7.86e-06 | 9.58e-05 | 7.14e-05 | 41 |
hsa0412033 | Endometrium | EEC | Ubiquitin mediated proteolysis | 41/1237 | 142/8465 | 7.86e-06 | 9.58e-05 | 7.14e-05 | 41 |
hsa0412026 | Esophagus | HGIN | Ubiquitin mediated proteolysis | 49/1383 | 142/8465 | 7.78e-08 | 1.33e-06 | 1.06e-06 | 49 |
hsa04120111 | Esophagus | HGIN | Ubiquitin mediated proteolysis | 49/1383 | 142/8465 | 7.78e-08 | 1.33e-06 | 1.06e-06 | 49 |
hsa0412027 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
hsa042156 | Esophagus | ESCC | Apoptosis - multiple species | 25/4205 | 32/8465 | 9.13e-04 | 2.92e-03 | 1.49e-03 | 25 |
hsa0412036 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
hsa0421511 | Esophagus | ESCC | Apoptosis - multiple species | 25/4205 | 32/8465 | 9.13e-04 | 2.92e-03 | 1.49e-03 | 25 |
hsa0412010 | Liver | NAFLD | Ubiquitin mediated proteolysis | 44/1043 | 142/8465 | 2.59e-09 | 1.70e-07 | 1.37e-07 | 44 |
hsa0412011 | Liver | NAFLD | Ubiquitin mediated proteolysis | 44/1043 | 142/8465 | 2.59e-09 | 1.70e-07 | 1.37e-07 | 44 |
Page: 1 2 3 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
BIRC6 | SNV | Missense_Mutation | novel | c.10793N>C | p.Asn3598Thr | p.N3598T | Q9NR09 | protein_coding | tolerated(0.16) | benign(0.007) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
BIRC6 | SNV | Missense_Mutation | c.2170N>C | p.Lys724Gln | p.K724Q | Q9NR09 | protein_coding | tolerated_low_confidence(0.06) | probably_damaging(0.999) | TCGA-CA-6718-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
BIRC6 | SNV | Missense_Mutation | rs747004451 | c.2658N>T | p.Lys886Asn | p.K886N | Q9NR09 | protein_coding | tolerated(0.25) | possibly_damaging(0.627) | TCGA-CA-6718-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
BIRC6 | SNV | Missense_Mutation | c.12068N>A | p.Ser4023Tyr | p.S4023Y | Q9NR09 | protein_coding | deleterious(0) | probably_damaging(0.964) | TCGA-CA-6718-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
BIRC6 | SNV | Missense_Mutation | c.13189N>A | p.Glu4397Lys | p.E4397K | Q9NR09 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-CA-6718-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
BIRC6 | SNV | Missense_Mutation | c.7588A>T | p.Thr2530Ser | p.T2530S | Q9NR09 | protein_coding | tolerated(0.38) | benign(0.121) | TCGA-CK-5916-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
BIRC6 | SNV | Missense_Mutation | c.3605N>T | p.Thr1202Met | p.T1202M | Q9NR09 | protein_coding | deleterious(0) | possibly_damaging(0.765) | TCGA-CM-4743-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | capecitabine | SD | |
BIRC6 | SNV | Missense_Mutation | c.4051N>A | p.Leu1351Ile | p.L1351I | Q9NR09 | protein_coding | tolerated(0.09) | probably_damaging(0.997) | TCGA-CM-4746-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
BIRC6 | SNV | Missense_Mutation | c.5026N>A | p.Val1676Met | p.V1676M | Q9NR09 | protein_coding | tolerated(0.07) | possibly_damaging(0.747) | TCGA-CM-6674-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
BIRC6 | SNV | Missense_Mutation | c.12035N>C | p.Val4012Ala | p.V4012A | Q9NR09 | protein_coding | tolerated(0.1) | benign(0.138) | TCGA-CM-6674-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |